The attainment of the licence places Oximio, South Africa, as a premier distributor for medical cannabis products for commercial or clinical trial purposes from Africa, extending the company’s reach to support the international market.
Mykola Nikolaiev, CEO, Oximio, says “this marks a significant turning point in our operations, exemplifying our commitment to supporting the use of medical cannabis in clinical trials whilst underscoring our commitment to maintaining the highest standards of quality and care.”